

3. (First time amended)

<sup>2</sup>  
The [A] composition of claim <sup>2</sup> wherein the monoclonal antibody has a tag to assist in identification of [the] an antibody/CS4-CFA/I protein complex.

Sub D3  
B<sup>2</sup>  
5. (First time amended)

~~The [A] composition of claim 4 wherein the tag is a colorometric tag.~~

4  
6. (First time amended)

<sup>3</sup>  
The [A] composition of claim <sup>3</sup> wherein the tag is a colorometric tag.

6  
8. (First time amended)

<sup>1</sup>  
A composition comprising [an] the antibody of claim [1] <sup>1</sup> in a pharmaceutically acceptable carrier.

B<sup>3</sup>  
7  
9. (First time amended)

<sup>6</sup>  
The [A] composition of claim <sup>6</sup> wherein the carrier is saline.

#### RESPONSE TO THE REJECTIONS OF RECORD

Claims 1-6, 8 and 9 have been rejected under 35 U.S.C. §112, first paragraph, as containing subject matter which was not described in the specification. Attached is an Declaration by the

15

B

undersigned stating that the deposit will be available in accord with the requirements of the U.S. Patent statutes and regulations. It is believed this rejection is thereby overcome.

Claims 1-6, 8 and 9 stand rejected under 35 U.S.C. 112, second paragraph as indefinite. It is believed most of the issues under this paragraph have been resolved by the amendments to the claims. However, the Examiner has suggested that the term CSF-CFA/I should recite full terminologies. However, the term is that used throughout the literature and would not be confusing to any one of skill in the art.

It is believed the claims are now in condition for allowance. If discussion would facilitate prosecution of this application, the Examiner is invited to contact the Applicant's representative at (703) 425-8405.

Respectfully Submitted;

  
Glenna Hendricks, Reg. No. 32535